Fortrea Holdings Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Fortrea is a global contract research organization serving biopharmaceutical and medical-device customers. It completed its spin-off from Labcorp on June 30, 2023 and began trading separately on July 3. Amounts below are in millions, except per-share data.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $776.4 | $762.3 | $2,333.6 | $2,334.4 |
| Operating income | $14.0 | $68.9 | $73.8 | $172.8 |
| Operating margin | 1.8% | 9.0% | 3.2% | 7.4% |
| Net income (loss) | $(13.1) | $60.6 | $32.6 | $159.5 |
| Diluted EPS | $(0.15) | $0.68 | $0.37 | $1.80 |
| Operating cash flow | Not provided for quarter | $155.0 | $59.2 |
- Q3 revenue increased 1.8% year over year, reflecting 1.0% organic growth and 0.8% favorable currency translation. Nine-month revenue was essentially flat.
- Q3 direct costs rose 8.8% to $647.3 and increased to 83.4% of revenue from 78.0%; nine-month direct costs rose 4.6% and reached 82.8% of revenue versus 79.1%. Higher pass-through, transition-service and personnel costs contributed; pass-through costs are offset by customer revenue.
- Q3 segment operating income fell to $59.9 for Clinical Services from $108.5 and to $2.3 for Enabling Services from $5.7. Nine-month segment operating income declined to $192.4 and $6.0, respectively. Management cited lower service revenue, new-business mix, a prior-year FSP cancellation, a customer concession, credit losses, and investment to serve a recent award.
- Q3 interest expense was $34.6, compared with none in the prior-year quarter, following debt incurred around the spin-off. Nine-month interest expense was $35.3.
- Cash was $107.5 at September 30, versus $112.0 at year-end 2022. Current assets were $1,257.8 and current liabilities $774.6. Debt carrying value was $1,598.5, including $26.1 current; cash-adjusted debt was approximately $1,491.0.
- Nine-month investing cash outflow was $22.8, including $30.9 capital expenditures. Financing cash outflow was $134.4, including the $1,595.0 special payment to Labcorp, substantially funded by debt proceeds. Cash declined $4.5 over the period.
Material changes, outlook and risks
- The spin-off materially changed the capital structure: Fortrea issued $570.0 of 7.50% senior notes and borrowed under term-loan facilities. Variable-rate debt was $1,062.3 at quarter-end; management estimated a 1 percentage-point rate increase would add about $10.6 to interest expense before swaps. A $450.0 revolving facility had no balance outstanding. The company was compliant with debt covenants.
- Management said cash, operating cash flows and available credit facilities should cover current and planned operations for at least the next 12 months. No specific earnings or revenue guidance was provided.
- Remaining long-term performance obligations were approximately $4,958.2; the company expects to recognize about 29% within 12 months. These obligations do not assure realization of all expected revenue.
- Restructuring actions to reduce overcapacity and align resources are expected to continue through 2023 and 2024. Q3 restructuring charges were $11.6; accrued restructuring costs of $7.9 were expected to be paid within 12 months.
- Key risks include customer cancellations or scope reductions, delayed or insufficient new business, contract pricing and cost overruns, macroeconomic conditions, foreign exchange and floating interest rates, transition-service dependence on Labcorp, and potential goodwill or intangible-asset impairment. One customer represented approximately 13.5% of Q3 revenue and 10.2% of nine-month revenue.
- Prior-year results are not fully comparable: periods before the spin are carve-out combined statements with Labcorp cost allocations, while post-spin periods reflect Fortrea as a standalone company. Transition services and standalone costs may affect expenses. The filing reports no legal matters expected to materially affect financial condition, results or cash flows.
Important facts for investors to verify
- Whether service revenue, new awards and customer retention improve, given modest revenue growth and steep segment-profit declines.
- How post-spin standalone and transition-service costs evolve relative to historical Labcorp allocations.
- Debt repayment capacity, floating-rate exposure, covenant headroom and the cost of interest.
- Receivable quality and collection trends: the credit-loss allowance rose to $28.3 from $12.7 at year-end 2022.
- Conversion of remaining performance obligations into recognized revenue, and the effect of customer concentration and cancellations.
- Whether restructuring delivers durable savings and whether goodwill and intangible assets remain recoverable.